Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase Inhibitor

Patent No. EP1849470 (titled "Anticancer Drug Containing Alpha, Alpha, Alphatrifluorothymidine And Thymidine Phosphorylase Inhibitor") was filed by Taiho Pharmaceutical on Jan 25, 2006. The application was issued on Mar 20, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMar 21, 2018TER MEER STEINMEISTER & PARTNER
STADA ARZNEIMITTELMar 21, 2018HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP1849470

TAIHO PHARMACEUTICAL
Application Number
EP06712292A
Filing Date
Jan 25, 2006
Status
Patent Maintained As Amended
Feb 16, 2024
Publication Date
Mar 20, 2024